EQRXW | EQRx, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0439 - 0.0640
52 Week Range	0.0439 - 0.0640
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	16,500
Average Volume	N/A
Shares Outstanding	25,067,057,560
Market Cap	1,140,551,119
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-12-20

Valuation
Profitability
Growth
Health
P/E Ratio	-0.01
Forward P/E Ratio	N/A
EPS	-7.65
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	216
Country	USA
Website	EQRXW

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1?antibody for the treatment of liver cancer. The company has partnerships with Exscientia and AbCellera Biologics Inc. EQRx, Inc. was founded in 2020 and is based in Cambridge, Massachusetts.

EQRXW's peers: AUROW, SONDW, CDROW, CINGW, DRTSW

*Chart delayed

Analyzing fundamentals for EQRXW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see EQRXW Fundamentals page.

Watching at EQRXW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on EQRXW Technicals page.